Kissei Pharmaceutical
Kissei Pharmaceutical Co Ltd is a company engaged in the manufacturing of specialty and generic drugs. Its operations are primarily focused on pharmaceuticals, with a significant portion of revenue generated in Japan and additional contributions from Europe. Kissei operates various subsidiaries to enhance its operational capabilities. The company also views mergers and acquisitions as a potential strategy for growth, aiming to expand its research, development, manufacturing, and marketing efforts.
Top Regions
1 past transactions
CG Oncology
Series D in 2020
CG Oncology, formerly known as Cold Genesys, is a privately held clinical-stage biopharmaceutical company specializing in the development of innovative oncolytic immunotherapies aimed at treating cancer. The company focuses on creating therapies that offer alternatives to conventional cancer treatments, particularly for patients with bladder cancer. Its lead candidate, cretostimogene grenadenorepvec, is a targeted intravesical immunotherapy agent designed to be delivered directly to the bladder. Currently, CG Oncology is conducting multiple clinical trials, including two phase three trials addressing high-risk and intermediate-risk non-muscle invasive bladder cancer (NMIBC), as well as a phase two study in combination with a checkpoint inhibitor for high-risk NMIBC. Through its research and clinical endeavors, CG Oncology aims to provide effective and less invasive treatment options for bladder cancer patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.